Selana 1 mg No. 28 pills


More info

Selana 1 mg No. 28 pills

Indications of the drug

Adjuvant treatment of early hormone-positive breast cancer in postmenopausal women, treatment of advanced breast cancer in postmenopausal women, adjuvant therapy of early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2–3 years.


Hypersensitivity, premenopausal period, concomitant therapy with tamoxifen or preparations containing estrogen; severe renal insufficiency (creatinine clearance <20 ml / min), moderate or severe liver failure (efficacy and safety not established), pregnancy, breast-feeding.

Use during pregnancy and lactation

Category of action on the fetus by the FDA - X.

Side effects

From the nervous system and sensory organs: asthenic syndrome, insomnia, drowsiness, anxiety, depression, headache, dizziness, paresthesia.

Since the cardiovascular system and blood (hematopoiesis, hemostasis): anemia, hypertension (severe dizziness, long-lasting headache), leukopenia with / without infection, thrombophlebitis, thromboembolism.

On the part of the respiratory system: dyspnea, sinusitis, rhinitis, bronchitis, pharyngitis.

On the part of the digestive tract: loss of appetite, nausea, vomiting, constipation / diarrhea, dry mouth.

Allergic reactions: including rash, pruritus, polymorphic erythema, Stevens-Johnson syndrome.

Others: hot flashes, vaginal dryness, vaginal bleeding, myalgia, arthralgia, chest pain, back pain, decreased mobility of joints, sweating, flu-like syndrome, peripheral edema, thinning hair and alopecia, hypercholesterolemia, increased levels of alkaline phosphatitis, AST and ALT ( patients with liver metastases), weight gain.

Precautionary measures

In women with a receptor-negative tumor to estrogen, the effectiveness of anastrozole has not been demonstrated, except in cases where there was a previous positive clinical response to tamoxifen. The efficacy and safety of anastrozole and tamoxifen with their simultaneous use, regardless of the status of hormonal receptors, are comparable to those when using tamoxifen alone (the exact mechanism of this phenomenon is not yet known).

In case of doubts about the hormonal status of the patient, the menopause should be confirmed by determining the sex hormones in the blood serum.

In case of persistent uterine bleeding while receiving anastrozole, consultation and supervision of a gynecologist is necessary.

Estrogen containing preparations should not be administered concurrently with anastrozole, since these drugs will level its pharmacological action.

By reducing circulating estradiol, anastrozole may cause a decrease in bone mineral density. In patients suffering from osteoporosis or at risk of developing osteoporosis, bone mineral density should be assessed by densitometry (for example, DEXA-scan) at the beginning of treatment and in the dynamics. If necessary, treatment or prevention of osteoporosis should be initiated under the close supervision of a physician.

There is no data on the simultaneous use of anastrozole and LHRH-analogue drugs (releasing hormone luteinizing hormone).

It is not known whether anastrozole improves the results of treatment when used in combination with chemotherapy.

Some side effects of anastrozole, such as asthenia and drowsiness, may adversely affect the ability to perform potentially hazardous activities that require increased concentration and psychomotor speed. In this regard, it is recommended that when these symptoms occur, caution should be exercised when driving vehicles and machinery.

Drug storage conditions

In a dry, dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.

Shelf life of the drug

3 years.

It is a pharmaceutical drug. Use only as directed by your doctor.